Literature DB >> 10668717

Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis.

K Jahn1, C Franke, J Bufler.   

Abstract

OBJECTIVE: To clarify the mechanism of block of nicotinic receptor channels by myasthenic antibodies.
BACKGROUND: Nicotinic acetylcholine receptor (nAChR) channel currents are functionally blocked by purified immunoglobulin G (IgG) of patients with myasthenia gravis (MG).
METHODS: The molecular mechanism of block of IgG fractions containing antibodies to nAChR channels was tested with the patch-clamp technique in combination with a system for ultrafast solution exchange. For the experiments, outside-out patches from cultured mouse myotubes that express embryonic-type nAChR channels at their surface were used.
RESULTS: Incubation of outside-out patches with purified IgG from four myasthenic patients blocked nAChR channel currents activated by the application of 1.0 mM ACh reversibly. The peak current amplitude and the time course of block of nAChR channels decreased with increasing concentrations of IgG. The block became at least partly irreversible if incubation time of outside-out patches exceeded 2 minutes. For the block of nAChR channel currents with a-bungarotoxin, a similar mechanism of block was found.
CONCLUSIONS: The reversibility of functional block of nAChR channel currents by myasthenic IgG depended strongly on the incubation time of the receptors with antibodies. Interaction of myasthenic antibodies with nicotinic receptors may proceed in several stages from a low-affinity reversible to a high-affinity irreversible binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10668717     DOI: 10.1212/wnl.54.2.474

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies.

Authors:  Emilia H Moscato; Ankit Jain; Xiaoyu Peng; Ethan G Hughes; Josep Dalmau; Rita J Balice-Gordon
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

2.  Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions.

Authors:  Rumi Sato; Shiho Imamoto; Iku Utsnomiya; Terumasa Chiba; Kyoji Taguchi; Kenji Abe; Keiko Tanaka; Tadashi Miyatake
Journal:  Neurol Sci       Date:  2013-02-07       Impact factor: 3.307

3.  Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development.

Authors:  Anne Taraldsen Heldal; Geir Egil Eide; Fredrik Romi; Jone Furlund Owe; Nils Erik Gilhus
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 4.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

5.  Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs.

Authors:  Hakan Cetin; Richard Webster; Wei Wei Liu; Akiko Nagaishi; Inga Koneczny; Fritz Zimprich; Susan Maxwell; Judith Cossins; David Beeson; Angela Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-12       Impact factor: 10.154

Review 6.  Ion channels as therapeutic antibody targets.

Authors:  Catherine J Hutchings; Paul Colussi; Theodore G Clark
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

7.  In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients.

Authors:  Henner Koch; Cristina E Niturad; Stephan Theiss; Christian G Bien; Christian Elger; Klaus-Peter Wandinger; Angela Vincent; Michael Malter; Peter Körtvelyessy; Holger Lerche; Marcel Dihné
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.